Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib, have been proven to efficiently inhibit the proliferation of a subset of non small-cell lung cancers (NSCLC). Unfortunately, the majority of NSCLC expressing wild type EGFR is primarily resistant to EGFR-TKI...
Guardado en:
Autores principales: | Anke Bill, Anton Schmitz, Katharina König, Lukas C Heukamp, Jeffrey S Hannam, Michael Famulok |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/abcd96ca8a6243b0bebc9a26e3465d5a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
por: Shuang Zhao, et al.
Publicado: (2021) -
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
por: Gang Chen, et al.
Publicado: (2013) -
Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Vamsidhar Velcheti, et al.
Publicado: (2010) -
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
por: Sugiura Y, et al.
Publicado: (2013) -
Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer
por: Chuncao Xu, et al.
Publicado: (2021)